Novolog (NVLG) Q1 2026 earnings summary

Executive summary

• Completed sale of 100% of Novohalet for NIS 14.5 million and signed agreement to sell part of Pronto Diagnostics' operations for up to NIS 1.5 million, both post-period events.

• Management changes: two directors resigned and two new directors appointed in May 2026.

• Ongoing impact from military operations and northern conflict, with logistics and healthcare segments reporting profit declines due to disruptions.

Financial highlights

• Revenue for Q1 2026: NIS 505.8 million, nearly unchanged year-over-year; gross profit: NIS 31.1 million.

• Net income attributable to shareholders: NIS 4.1 million, up from NIS 1.0 million in Q1 2025.

• Adjusted EBITDA: NIS 24.4 million, down from NIS 33.6 million year-over-year.

• Cash flow from operations: negative NIS 0.7 million, improved from negative NIS 109.6 million in Q1 2025.

Outlook and guidance

• Company continues to monitor and mitigate the impact of ongoing military conflict and intends to take further actions to reduce negative effects on results.

• Strategic focus on divesting non-core assets and streamlining operations.